✍️ Antibody-Drug Conjugates (ADC) vs Targeted Protein Degraders (TPD): Mastering the Core Technologies of Next-Gen Targeted Therapies (2025 Update)
🔍 Introduction
In recent years, the field of cancer treatment has undergone a rapid transformation centered around the concept of precision medicine. At the forefront of this shift are two groundbreaking technologies: Antibody-Drug Conjugates (ADC) and Targeted Protein Degraders (TPD). Both represent highly specific, next-generation therapeutic strategies that go beyond conventional chemotherapy—offering more effective treatment with fewer side effects and driving innovation across the biopharmaceutical industry.
🔬 ADC vs TPD: What’s the Difference?
| Category | Antibody-Drug Conjugates (ADC) | Targeted Protein Degraders (TPD) |
|---|---|---|
| Mechanism | Antibody delivers a cytotoxic drug to specific cancer cells | Target protein is ubiquitinated and degraded via proteasome |
| Core Technology | Antibody + Linker + Cytotoxic Payload | PROTAC, Molecular Glue, etc. |
| Target Focus | Cancer cell surface antigens | Intracellular proteins, including enzymes and disease drivers |
| Market Readiness | Multiple FDA-approved products (e.g., Enhertu, Kadcyla) | In clinical trials (e.g., ARV-471 in FDA Fast Track process) |
| Therapeutic Areas | Solid tumors (e.g., breast, lung, lymphoma) | Breast, prostate cancers, autoimmune and rare diseases |
📚 Scientific Evidence: Literature Review
✅ Korean Journal of Internal Medicine (2023)
→ ADCs enable precise drug delivery and reduce toxicity in solid tumors, showing significant survival benefits in HER2+ breast cancer.
Source: [Korean J. Internal Med., 2023]
✅ BRIC Review (2024)
→ TPDs eliminate disease-causing proteins altogether, overcoming drug resistance while offering flexible molecular design across diverse indications.
Source: [BRIC BioTech Trends, 2024]
🌍 Leading Companies & Clinical Pipeline
✅ ADC Leaders
- Roche (Kadcyla): HER2+ breast cancer
- Daiichi Sankyo (Enhertu): Next-gen linker technology
- Seagen (Adcetris): Leading ADC for blood cancers
✅ TPD Leaders
- Arvinas (ARV-471): Phase 2 for breast cancer
- Kymera Therapeutics (KT-474): Clinical trials for autoimmune diseases
- C4 Therapeutics (CFT8634): Targeting rare tumors
🔚 Conclusion
Both ADC and TPD technologies represent transformative approaches in the realm of precision medicine.
- ADC focuses on precise delivery of potent drugs to cancer cells.
- TPD represents a paradigm shift by completely removing disease-causing proteins from cells.
Together, they are poised to expand their impact beyond oncology into autoimmune and neurological diseases. As pharmaceutical giants invest heavily in these technologies, ADCs and TPDs are set to become pillars of the next generation of therapeutics.